Method for improving recombinant human epidermal growth factor by using codon preference of polyhedrosis protein gene
By redesigning the amino acid codon of human epidermal growth factor hEGF and using the baculovirus expression system of silkworm, the problem of low expression level of recombinant hEGF is solved, and efficient and low-cost hEGF production is achieved, which has important genetic engineering application value.
Patent Information
- Application Number
- CN202411013196.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, the expression level of the recombinant human epidermal growth factor hEGF is low, the cost is high, and the secondary structure is far from that of natural hEGF, which cannot meet market demand.
The amino acid codon of human epidermal growth factor hEGF was redesigned using the codon preference of the polyhedral protein gene of silkworm baculovirus, and the recombinant baculovirus was constructed through the Bac-to-Bac recombinant baculovirus expression system to achieve high-level expression.
It significantly improves the expression level of recombinant hEGF, reduces production costs, provides innovative technologies for large-scale production, and has important genetic engineering application prospects.
Smart Images

Figure CN118955681A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of molecular biotechnology, and in particular relates to a method for increasing recombinant human epidermal growth factor by utilizing the codon preference of polyhedrin gene. Background Art
[0002] Human Epidermal Growth Factor (hEGF) was first discovered and identified by Gregory in human urine in 1975. It is a small molecule polypeptide composed of 53 amino acids with a molecular weight of about 6.2kD. hEGF can regulate and promote the growth and proliferation of epidermal cells and repair skin tissue. It can be used clinically to treat surgical trauma (burns, scalds, etc.), skin ulcers, corneal damage, tissue repair, etc. In addition, hEGF, as a mitogen, can promote the proliferation, differentiation and migration of epidermal cells, thereby accelerating cell metabolism, thereby moisturizing the skin and delaying aging. Therefore, it is loved by the cosmetics and medical beauty industries and is called the "beauty factor."
[0003] At present, the main sources of recombinant hEGF are human cells, yeast and E. coli. It is costly to obtain hEGF through human cells, and the yield is low, which is difficult to meet market demand. The E. coli expression system cannot achieve complex modifications of protein expression, and the ability to form disulfide bonds is limited, so the secondary structure of the expressed hEGF protein is far different from that of natural hEGF. Its biological activity is not as good as that of hEGF from eukaryotic expression systems or mammalian sources, and it is easy to form inclusion bodies. The yeast expression system is currently the most effective system for producing hEGF protein, but it only contains 51 amino acids at the N-terminus of hEGF instead of complete hEGF, the expression amount is not high, and the cost is high. The baculovirus expression vector system has relatively complete protein post-translational processing and modification functions, such as the formation of disulfide bonds, which can maintain the original structure and biological activity of exogenous proteins to a large extent. According to existing reports, the baculovirus expression vector system can express active hEGF protein, but the expression amount is low. Summary of the invention
[0004] In order to solve the problems in the background technology, the purpose of the present invention is to provide a method for improving the production of recombinant human epidermal growth factor by utilizing the codon preference of the polyhedrin gene, aiming to significantly increase the expression level of recombinant human hEGF and improve the production amount and efficiency of recombinant human epidermal growth factor.
[0005] In order to achieve the above-mentioned invention object, the technical solution adopted by the present invention is as follows:
[0006] 1. A recombinant human epidermal growth factor with preference, wherein the recombinant human epidermal growth factor hEGFb is a protein, and its DNA sequence is SEQ ID NO.1.
[0007] 2. A method for increasing recombinant human epidermal growth factor by utilizing the codon preference of polyhedrin gene, comprising constructing and synthesizing the recombinant human epidermal growth factor hEGFb; and culturing and expressing the recombinant human epidermal growth factor hEGFb by utilizing a viral expression system.
[0008] The recombinant human epidermal growth factor hEGFb is constructed by redesigning each amino acid codon in the human epidermal growth factor hEGF according to the preference of each amino acid codon in the polyhedrin gene polyhedrin and adding BamHI and HindIII restriction endonuclease sites at both ends.
[0009] The recombinant human epidermal growth factor hEGFb is cultured and expressed by using a viral expression system, specifically: the gene sequence of the recombinant human epidermal growth factor hEGFb cut by BamHI and HindIII is cloned into the donor plasmid pFastBacHTb (see Figure 1 ) to generate the recombinant plasmid pFastBacHTb-hEGFb, and then transform the recombinant plasmid pFastBacHTb-hEGFb into DH10BmBac bacterial competent cells containing BmNPV Bacmid (see Figure 2 and instructions), inserting the recombinant human epidermal growth factor hEGFb into the silkworm baculovirus genome Bacmid through the transposition of bacterial transposon to obtain the recombinant baculovirus Bacmid, identifying the recombinant Bacmid by screening blue and white spots, further extracting the recombinant Bacmid and transfecting it into silkworm culture cells to produce the recombinant baculovirus expressing the recombinant human epidermal growth factor hEGFb;
[0010] The recombinant baculovirus constructed above was inoculated into silkworm culture cells, and the cells were collected 96 hours after infection to extract the recombinant human epidermal growth factor hEGFb.
[0011] 3. A method for increasing the recombinant human epidermal growth factor by utilizing the codon preference of the polyhedrin gene, prepared by the above method:
[0012] The recombinant human epidermal growth factor hEGFb is used in beauty and anti-aging for non-therapeutic purposes.
[0013] The present invention utilizes the fact that the polyhedrin gene, a gene encoded by the silkworm baculovirus, exhibits an extremely high expression level in the very late stage of the virus infection, and then analyzes the codon preference of the gene, redesigns the human epidermal growth factor (hEGF) codon, and constructs a recombinant baculovirus capable of expressing hEGF with this new codon, thereby achieving high-level expression of the recombinant hEGF.
[0014] Specifically, the present invention utilizes the codon preference principle of the super-high expression gene Polyhedrin of the silkworm baculovirus BmNPV, redesigns the human hEGF gene codon, synthesizes the new DNA coding sequence of the hEGF, and further utilizes the silkworm Bac-to-Bac baculovirus expression system to construct a recombinant baculovirus capable of expressing hEGF. By infecting silkworm cultured cells, it is analyzed that the gene has a high expression efficiency, and compared with the unmodified original sequence, the level of the recombinant hEGF protein has been greatly improved ( Figure 3 ).
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] The method of the present invention belongs to the field of molecular biotechnology. Compared with the currently published research results, the method of the present invention significantly improves the expression level of recombinant human hEGF, can greatly reduce the production cost of recombinant hEGF, and provides a significantly innovative technology for the large-scale production of recombinant human hEGF.
[0017] The technology of the present invention has important reference significance for improving some recombinant proteins with low expression levels and has broad application prospects in the field of genetic engineering. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 This is a schematic diagram of the donor plasmid pFastBacHT. In the figure, Tn7L and Tn7R are the left and right arms of the bacterial transposon, respectively, which undergo gene transposition under the action of bacterial transposase.
[0019] Figure 2 It is a competent cell containing Bacmid. The cell contains the modified baculovirus genome Bacmid, which has a transposition recognition site. Helper is an auxiliary plasmid that expresses transposase. Under the action of the transposase, the left and right transposition arms on pFastBacHT are transferred to the transposition site on Bacmid, completing the insertion of the gene, thereby producing a recombinant Bacmid.
[0020] Figure 3 It is the SDS-PAGE analysis electrophoresis diagram of the expression level of recombinant hEGF after codon modification. DETAILED DESCRIPTION
[0021] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0022] Embodiments of the present invention are as follows:
[0023] (1) Codon analysis of the polyhedrin gene, a gene expressed at a very high level in the late stage of Bombyx mori baculovirus (BmNPV):
[0024] The nucleotide sequence of the polyhedrin gene, polyhedrin, a very late and highly expressed gene of the silkworm BmNPV, and the corresponding encoded amino acid sequence were obtained from the DNA sequence database of GenBank, and the codons used for each amino acid were sorted out (see Table 1), and the codons with the highest frequency of use corresponding to each amino acid were further analyzed;
[0025] Table 1. Analysis of codon preference of BmNPV polyhedrin
[0026]
[0027]
[0028] (2) Human epidermal growth factor hEGF gene and codon design:
[0029] The nucleotide sequence and encoded amino acid sequence of human epidermal growth factor hEGF gene were obtained from GenBank. According to the preference of each amino acid codon in the above-mentioned polyhedrin gene polyhedrin, each amino acid codon in hEGF was redesigned and replaced with codons consistent with the preference of the polyhedrin gene (see Table 2). BamHI and HindIII restriction endonuclease sites were added to both ends of the gene, respectively. This new DNA sequence (named hEGFb, b means bias) was commissioned to a company for synthesis.
[0030] Table 2 Comparison of the original sequence of human hEGF and the sequence after codon modification
[0031]
[0032] In the step (2), the hEGF codons are redesigned and synthesized.
[0033] (3) Construction of recombinant baculovirus expressing hEGF:
[0034] According to the constructed Bac-to-Bac recombinant baculovirus expression system suitable for silkworm, the hEGFb sequence digested by BamHI and HindIII (the same operation was performed on the original sequence hEGF in the experiment, set as the control group CK) was cloned into the donor plasmid pFastBacHTb to generate the recombinant plasmid pFastBacHTb-hEGFb, and then the plasmid was transformed into DH10BmBac bacterial competent cells containing BmNPVBacmid, and the hEGFb gene was inserted into Bacmid through the transposition of the transposon, and the recombinant Bacmid was identified by blue-white screening on a culture plate containing antibiotics such as anka penicillin and kanamycin, and the recombinant Bacmid was further extracted and transfected into silkworm culture cells to generate recombinant baculovirus expressing recombinant human epidermal growth factor hEGFb and human epidermal growth factor hEGF;
[0035] The step (3) is to construct a recombinant baculovirus for expressing the new sequence hEGFb generated by the new codon design.
[0036] (4) Analysis of recombinant hEGF expression: The recombinant viruses (including controls) constructed above were inoculated into silkworm cultured cells, and the cells were collected 96 hours after infection. The expression level of recombinant hEGF was analyzed by SDS-PAGE electrophoresis.
[0037] The step (4) is to infect silkworm cells with the newly constructed recombinant hEGF baculovirus and analyze the expression level of the recombinant hEGF.
[0038] Note: The yellow marks are restriction endonuclease sites, the red marks are stop codons, and the blue marks are 6*His sequences used for purification.
[0039] Example: SDS-PAGE analysis of the expression level of recombinant hEGF after codon modification Figure 3 As shown in the figure, the leftmost lane is the standard molecular weight; the middle lane is the result of the expression of the original codon sequence of the control group CK, and the specific band is very weak; the rightmost lane is the result of the expression of the sequence designed and synthesized with the new codon. The molecular weight of hEGF is 8.2KDa, and it is about 11.2KDa with the linker sequence such as 6*His. Figure 3 It can be seen that the expression level of recombinant hEGF has been greatly increased.
[0040] The above specific implementation modes are used to explain the present invention rather than to limit the present invention. Any modification and change made to the present invention within the spirit of the present invention and the protection scope of the claims shall fall within the protection scope of the present invention.
[0041] The above description is only a preferred embodiment of the present invention, so all equivalent changes or modifications made according to the structure, characteristics and principles described in the scope of the patent application of the present invention are included in the scope of the patent application of the present invention.
[0042] The amino acid sequence designed by the present invention is as follows:
[0043] SEQ ID No.1;
[0044] Name: DNA sequence of recombinant human epidermal growth factor hEGFb
[0045] DNA type: unassigned DNA
[0046] Biological source: Artificial sequence / synthetic construct
[0047] GGATCCAACAGCGACAGCGAGTGCCCCCTCAGCCACGACGGCTACTGCCTCCATGACGGCGTGTGCATGTACATCGAGGCCCTCGACAAATACGCCTGCAACTGCGTGGTGGGCTACATCGGCGAGCGCTGCCAATACCGCGACCTCAAATGGTGGGAGCTCCGCCATCACCATCACCATCACTAAAAGCTT.
Claims
1. A recombinant human epidermal growth factor, characterized in that: The DNA sequence of the recombinant human epidermal growth factor hEGFb is SEQ ID NO.
1.
2. A method for increasing recombinant human epidermal growth factor by utilizing the codon preference of polyhedrin gene, characterized in that: The method comprises the following steps: constructing and synthesizing the recombinant human epidermal growth factor hEGFb described in claim 1; and culturing and expressing the recombinant human epidermal growth factor hEGFb using a viral expression system.
3. The method of claim 2, wherein the method comprises: The recombinant human epidermal growth factor hEGFb is constructed by redesigning each amino acid codon in the human epidermal growth factor hEGF according to the preference of each amino acid codon in the polyhedrin gene polyhedrin and adding BamHI and HindIII restriction endonuclease sites at both ends.
4. The method of claim 2, wherein the method comprises: The use of a viral expression system to culture and express the recombinant human epidermal growth factor hEGFb is specifically: According to the silkworm Bac-to-Bac recombinant baculovirus expression system, the gene sequence of recombinant human epidermal growth factor hEGFb cut by BamHI and HindIII is cloned into the donor plasmid pFastBacHTb to produce the recombinant plasmid pFastBacHTb-hEGFb, and then the recombinant plasmid pFastBacHTb-hEGFb is transformed into DH10BmBac bacterial competent cells containing BmNPV Bacmid, and the recombinant human epidermal growth factor hEGFb is inserted into the silkworm baculovirus genome Bacmid through the transposition of bacterial transposon to obtain the recombinant baculovirus Bacmid, and the recombinant Bacmid is identified by screening blue and white spots, and the recombinant Bacmid is further extracted and transfected into silkworm cultured cells to produce the recombinant baculovirus expressing the recombinant human epidermal growth factor hEGFb; the recombinant baculovirus constructed as above is inoculated into the silkworm cultured cells, and the cells are collected 96 hours after infection to extract the recombinant human epidermal growth factor hEGFb.
5. A method for increasing recombinant human epidermal growth factor by utilizing the codon preference of polyhedrin gene, characterized in that: The method is prepared by any one of claims 2 to 4.
6. A use of the recombinant human epidermal growth factor according to claim 1 or the recombinant human epidermal growth factor according to any one of claims 2 to 4, characterized in that: The recombinant human epidermal growth factor hEGFb is used in beauty and anti-aging for non-therapeutic purposes.
Citation Information
Patent Citations
Human epidermal growth factor hEGF gene optimization sequence, method for preparing same and application of human epidermal growth factor hEGF gene optimization sequence
CN107254472A
Recombinant expression of PCV2B ORF2 protein in insect cells
CN111212847A
Protein of human epidermal growth factor fusion functional polypeptide as well as preparation method and application thereof
CN113004425A
Human epidermis factor nucleic sequence and use thereof
CN1644691A
